93470-26-9

Usage

Uses

Used in Polymer Synthesis:
(R)-1-Cyclohexylethyl isocyanate is used as a monomer in the polymer industry for the synthesis of various polymers. Its high reactivity and ability to rapidly polymerize make it an ideal component for creating polyurethanes and polyureas, which are widely used in various applications due to their unique properties.
Used in Coatings and Adhesives:
In the coatings and adhesives industry, (R)-1-Cyclohexylethyl isocyanate is used as a reactive diluent or cross-linking agent. Its ability to form strong bonds and improve the mechanical properties of the final product makes it a valuable component in the formulation of high-performance coatings and adhesives.
Used in Flexible and Rigid Foams:
(R)-1-Cyclohexylethyl isocyanate is utilized in the production of flexible and rigid foams, which are used in various applications such as insulation, cushioning, and packaging materials. Its role in the formation of these foams contributes to their desirable properties, including thermal insulation, lightweight, and dimensional stability.
Used in Elastomers and Rubber:
In the elastomers and rubber industry, (R)-1-Cyclohexylethyl isocyanate is employed as a key ingredient in the synthesis of high-performance elastomers and rubber materials. Its incorporation into these materials enhances their mechanical properties, such as tensile strength, abrasion resistance, and flexibility, making them suitable for various applications, including automotive, industrial, and consumer products.
Used in Surface Treatments:
(R)-1-Cyclohexylethyl isocyanate is also used in surface treatments to improve the adhesion, durability, and chemical resistance of various materials. Its reactive nature allows it to form strong bonds with different substrates, making it an effective component in surface treatment formulations for applications such as automotive coatings, marine coatings, and protective coatings for metal and plastic surfaces.

InChI:InChI=1/C9H15NO/c1-8(10-7-11)9-5-3-2-4-6-9/h8-9H,2-6H2,1H3/t8-/m1/s1

Upstream product

• 5913-13-3 [(1R)-1-cyclohexylethyl]amine 
• 503-38-8 trichloromethyl chloroformate 
• 32315-10-9 bis(trichloromethyl) carbonate 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of making these compounds or pharmaceutically acceptable sal

PROLINE UREA CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES & INFLAMMATION

Compounds of the formulae (I) and (II) are disclosed. The compounds are CCRl antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.

Influence of bulky substituents on histamine H3 receptor agonist/antagonist properties

Novel derivatives of 3-(1H-imidazol-4-yl)propanol were designed on the basis of lead compounds belonging to the carbamate or ether series possessing (partial) agonist properties on screening assays of the histamine H3 receptor. One pair of enantiomers in the series of α-methyl-branched chiral carbamates was stereoselectively prepared in high optical yields. Enantiomeric purity was checked by Mosher amide derivatives of precursors and capillary electrophoresis of the final compounds with trimethyl-β-cyclodextrin as chiral selector, and was determined to be ≥95%. The novel compounds were investigated in various histamine H3 receptor assays in vitro and in vivo. Some compounds displayed partial agonist activity on synaptosomes of rat brain cortex, whereas others exhibited antagonist properties only. Selected compounds were investigated in [125I]iodoproxyfan binding studies on the human histamine H3 receptor and showed high affinity in the nanomolar concentration range. Under in vivo conditions after oral administration to mice, some of the compounds exhibited partial or full agonist activity in the brain at low dosages. The (S)-enantiomer of one pair of chiral carbamates (9) proved to be the eutomer; thus, the (S)-enantiomer was selected for further pharmacological studies. In a peripheral in vivo test model in rats, measuring the level of inhibition of capsaicin-induced plasma extravasation, (S)-9 again proved its high oral agonist potency with full intrinsic activity (ED50 values of 0.07-0.1 mg/kg depending on tissue).